Company

The Ingenix team was built deliberately to do work that no single discipline can address alone.

Bridging AI and Biology

On the AI side, the founding team previously built the AI company Applica—later acquired by Snowflake—whose TILT model contributed to the GPT-4 benchmark. The wider research team includes Kaggle Grandmasters and AI researchers who came to Ingenix from Recursion, Inceptive, and Snowflake.

On the biology side, the team brings pharma research experience spanning discovery through Phase II, including ex-InSilico Medicine veterans and a computational biologist ranked in the top 2% globally by a Stanford study. The Global Head of R&D Oncology at Servier serves as a Scientific Advisor.

On the commercial side, leadership has the business experience this sector requires. From seven years of experience supporting AI and life sciences startups at Amazon Web Services to having co-founded AION Labs as a venture builder for AI-driven biotech, we know what it takes to get an AI partnership to land inside a top-20 pharma organization.

Why devote our careers to building AI that truly understands biology? The decisions made early in R&D compound over every phase that follows—better questions early mean fewer failed trials, more therapies that work, and fewer patients without access to care. We like being part of the solution.

As a company we promote a culture of accountability and rigorous adhesion to the scientific method. Ingenix is strongly in favor of human-mediated AI, both on ethical grounds and because we believe unchecked falsehoods are simply bad for business.
The result is an AI partner that reasons across every biological scale simultaneously—and shows its work. A force multiplier for the R&D leaders making the next decision.

Leadership

Piotr Surma—CEO & Co-Founder

CEO & Co-Founder

Co-founder and former CEO of Applica, the AI company acquired by Snowflake in 2022. At Ingenix, Piotr leads the company’s overall direction, strategy, and scientific vision.

Adam Dancewicz

CTO & Co-Founder

Co-founder and former CTO of Applica, where he led the development of the multimodal document-understanding LLMs acquired by Snowflake—including the TILT model that contributed to the GPT-4 benchmark. At Ingenix, Adam leads the engineering and architecture of the Biological Reasoning Engine.

Guy Spigelman

Chief Business Officer

Previously EMEA lead for Healthcare & Life Sciences Startups at Amazon Web Services, where he spent seven years working with early-stage AI and biotech companies as they built and scaled. Co-founder of AION Labs, the AI-driven biotech venture builder. Earlier career in venture capital and early-stage startups. At Ingenix, Guy leads commercial strategy, partnerships, and the Qualified Access Program.

Tomasz Jetka

PhD—Lead Scientist

Previously Senior Scientist at InSilico Medicine, where he co-developed PandaOmics and contributed to the development of the drug rentosertib. Later Director of AI and Data Science at Ardigen, leading projects across drug discovery and development. His PhD covered Maths, Computational Biology and wet lab work with Phenotypic Screening. At Ingenix, Tomasz leads the scientific work at the intersection of AI and biology, including the design of the engine’s reasoning workflows.

Tomasz Stanisławek

PhD—Head of AI Research

Previously Senior Engineering Manager at Snowflake, where he led research teams following the Applica acquisition. PhD in Computer Science from Warsaw University of Technology, with a research focus on natural language processing, document understanding, and deep learning. Co-author of multiple peer-reviewed publications on multimodal language models. At Ingenix, Tomasz leads AI research and the development of the Biological Reasoning Engine’s core architecture.

Scientific Advisor

Walid S. Kamoun

PhD, MSc

Vice President and Global Head of R&D Oncology at Servier, where he leads development of Servier’s oncology pipeline and the “One Innovation Engine” R&D strategy. Previously Head of Cell Therapy and Early Translational Oncology at Takeda Pharmaceuticals. PhD in Vascular Biology, MSc in Quantitative Image Analysis, with postdoctoral training in cancer research at Harvard Medical School. Walid advises Ingenix on translational and clinical strategy in oncology.